June 19, 2018, 10:00 EST | 15:00 GMT | 16:00 CET
Current deformulation scientists face MASSive exSPECtations—they are required to detect, screen, and identify unknowns with increasing efficiency despite shrinking analytical group sizes, pressure to perform more diverse activities, increased outsourcing of work, and slow, tedious, and error-prone methods. As a result analysts are left with much less time to devote to complex deformulation projects, while being expected to streamline existing analytical procedures.
Watch this webinar to see how ACD/Labs' MS tools can ensure you meet your own MASSive exSPECtations in deformulation! We'll discuss our industry leading unknown identification MS tools, which will enable you to meet your deconvolution challenges through an effective and efficient workflow that isolates all unknowns, rapidly screens them against chemical databases, and transparently identifies the best structure candidate(s).
Enter your contact info to watch the webinar today!
In this webinar you will learn how to use ACD/Labs MS analysis software to:
Dr. Anne Marie Smith (Application Scientist) received her Ph.D. in Chemical Biology from McMaster University where she developed MALDI-MS based assays for screening aminoglycoside kinases. After graduating she was employed as an Associate Scientist with Gilead Sciences in Edmonton, Alberta where the majority of her work focused on impurity identification by LC-MS and LC method development. She later held a position at Piramal Healthcare in Aurora, Ontario as an Analyst where she developed methods by LC, GC, and LC-MS. Anne Marie then joined ACD/Labs where she has successfully applied her detailed knowledge of many analytical techniques, especially Mass Spectrometry and Chromatography, as well as hands-on experience with instruments, troubleshooting technical issues, using scientific software packages, and chromatographic method validation.
Dr. Richard Lee (Senior Manager, Core Capability & Technology) obtained his Ph.D. from McMaster University in Canada, where his area of study focused on strategies for metabolite identification and metabolomics studies. From McMaster, he moved on as a Scientist at the Centre of Probe Development and Commercialization "CPDC" in Hamilton, Ontario, which developed radiopharmaceuticals as imaging agents and therapeutics for oncology. In this capacity, he was involved in a number of initiatives, acting as project leader and technical leader for radiopharmaceuticals candidates, which were ultimately approved for clinical use by Health Canada and the FDA. He has been with ACD/Labs for the past 5 years and has regularly contributed to the development of ACD/Labs' MS tools, with a particular focus on novel metabolite identification solutions.